CounterACT Researchers & Projects

Countermeasures against chemical threats banner


CounterACT sites on U.S. map


Abstracts, budgets, and contact information for all CounterACT-supported  projects are available via the NIH RePORTER database


Research Centers of Excellence (U54)

UMDNJ/Rutgers University CounterACT Research Center of Excellence 
Jeffrey D. Laskin, Ph.D.
RBHS-School of Public Health
U54AR055073

Development of Antidotes for Toxic Gases
Carl W. White, M.D.
University of Colorado, Denver
U54ES027698

Novel Anticonvulsant and Neuroprotective Therapies for TETS and OP Intoxication 
Pamela J. Lein, Ph.D.
University of California, Davis
U54NS079202

A Discovery and Development Pipeline for Cyanide Countermeasures
Calum A. MacRae, M.D., Ph.D.
Brigham and Women's Hospital
U54NS079201

 


Individual Research Projects (U01)

Effective Therapies for Ocular Injuries by Vesicating Agents
Rajesh Agarwal, Ph.D.
University of Colorado, Denver
U01EY023143

Extracellular RNA as Therapeutic Target After Toxic Chemical Inhalation
Aftab Ahmad, Ph.D.
University of Alabama, Birmingham
U01ES025069

Targeting Cardiopulmonary Calpains to Mitigate Toxicity of Halogen Gases
Shama Ahmad, Ph.D.
University of Alabama, Birmingham
U01ES028182

Blocking Arsenicals-induced Cutaneous Injury
Mohammad Athar, Ph.D.
University of Alabama, Birmingham
U01NS095678

Preclinical and Clinical Studies of Cobinamide, a New Cyanide Detoxifying Agent 
Gerry R. Boss, M.D.  
University of California, San Diego
U01NS058030

Development of the Vitamin B12 Analog Cobinamide as a Hydrogen Sulfide Antidote 
Gerry R. Boss, M.D.  
University of California, San Diego
U01NS087964

Sodium Tetrathionate as a Cyanide Antidote 
Gerry R. Boss, M.D.  
University of California, San Diego
U01NS105057

Brain-Penetrating Acetylcholinesterase Reactivators for Several Organophophates
Janice E. Chambers, Ph.D.
Mississippi State University
U01NS083430

Novel Counteract Agents to Reduce Mortality and Morbidity Following Organophosphate Status Epilepticus 
Robert J. DeLorenzo, M.D., Ph.D., M.P.H.  
Virginia Commonwealth University
U01NS105058

Intralipid: A Novel Frontline Countermeasure for Brodifacoum Poisoning
Douglas L. Feinstein, Ph.D.  
University of Illinois, Chicago
U01NS083457

Pharmacotherapy to Counteract Parathion-induced NMJ Dysfunction
Romolo J. Gaspari, Ph.D.  
University of Massachusetts Medical School, Worchester
U01NS083452

Neurosteroids as a Standard Medical Countermeasure for OP Poisoning 
Kelvin W. Gee, Ph.D.    
University of California, Irvine
U01NS102131

Development of Therapeutics for Chlorine-induced Airway and Lung Injury 
Michael D. Gunn, M.D.
Duke University
U01ES017219

Methylene Blue an an Antidote Against Hydrogen Sulfide Intoxication
Philippe Haouzi, M.D.
Pennsylvania State University Hershey Medical Center
U01NS097162

Novel Therapies for Chlorine-Induced Lung Injury 
Gary W. Hoyle, Ph.D.    
University of Louisville
U01ES015673

Countermeasures for Chlorine-Induced Airway Fibrosis 
Gary W. Hoyle, Ph.D.    
University of Louisville
U01ES022564


Targeting Injury Pathways to Counteract Pulmonary Agent and Vesicant Toxicity 
Sven-Eric Jordt, Ph.D.
Duke University
U01ES015674

TIE2 Activation for the Treatment of Chemical-induced Acute Lung Injury
Christopher D. Kontos, Ph.D.
Duke University
U01ES028187

Developing Drugs to Mitigate Parathion Intoxication
Jeffrey D. Laskin, Ph.D.
RBHS-School of Public Health
U01NS079249

Functional Genomics of Chemical-induced Acute Lung Injury 
George D. Leikauf, Ph.D.    
University of Pittsburgh, Pittsburgh
U01ES015675

Amelioration of Vesicant-induced Skin Injury by High Dose 25-Hydroxyvitamin D 
Kurt Lu, M.D.
Case Western Reserve University 
U01AR064144

Translation of Novel and Repurposed Drugs to Address the Acute and Late Effects of Mustard Exposure 
Kurt Lu, M.D.
Case Western Reserve University 
U01AR071168

Bromine Inhalation Induced Lung Injury: Novel Mechanisms and Treatment Strategies
Sadis Matalon, Ph.D.
University of Alabama, Birmingham
U01ES026458

CIALIS® Reverses Halogen Induced Injury to Pregnant Animals and Their Offspring
Sadis Matalon, Ph.D.
University of Alabama, Birmingham
U01ES027697

Neuroprotective Effects of AEOL 10150 Against Organophosphate Toxicity
Manisha N. Patel, Ph.D.
University of Colorado, Denver
U01NS083422

Nitrite Dependent Protection Against Cl2 Gas Toxicity Role of Chlorinated Lipids
Rakesh Patel, Ph.D.
University of Alabama, Birmingham
U01ES023759

Accelerate AChE Reactivator Design by Mechanistic Neutron Scattering Studies
Zoran Radic, Ph.D.
University of California, San Diego
U01NS083451

Neurosteroid Treatment for OP Intoxication
Doodipala S. Reddy, Ph.D.
Texas A&M University Health Science Center
U01NS083460

Thioredoxin Mimicry: Novel Treatment of Toxicant-mediated Inhalational Lung Injury
Garry J. Southan, Ph.D.

Radikal Therapeutics, Inc.
U01ES024097

Molecular Imaging of Chemical Threats and Countermeasures
Charles M. Thompson, Ph.D.
University of Montana
U01NS092495

Rational Polytherapy in the Treatment of Cholinergic Seizures 
Claude G. Wasterlain, M.D.
Brentwood Medical Research Institute
U01NS074926

 


Small Business Innovation Research (SBIR)

Cyanalyzer a Medical Laboratory Device for the Rapid Diagnosis of Cyanide Exposure 
Randy Jackson, Ph.D.
Seacoast Science, Inc.
R44NS097066

Efficacy and Safety of an Aerosolized Recombinant Butyrylcholinesterase Pretreatment
Yvonne Rosenberg, Ph.D.
Plantvax, Inc.
R44NS064608

 


Exploratory/Developmental Projects (R21)

Targeting the Glutamatergic System to Counteract Soman Toxicity in Immature Rats
Maria F.M. Braga, D.D.S., Ph.D.
Henry M Jackson Foundation for the Advancement of Military Medicine
R21NS094131

Antidotes Against Hydrochloric Acid-induced Chronic Lung Injury
John D. Cantravas, Ph.D.
Old Dominion University
R21ES029309

Therapy for Ocular Mustard Gas Exposure Using Engineered FGF Derivatives
David D. Eveleth, Ph.D.
E&B Technologies, LLC
R21EY026777

Effects of Acute Administration of the Phenothiazinium Chromophore Methylene Blue During Life Threatening Cyanide Intoxication
Philippe Haouzi, M.D.
Pennsylvania State University Hershey Medical Center
R21NS098991

Treatment of Persistent Chlorine-induced Small Airway Disease 
Gary W. Hoyle, Ph.D.    
University of Louisville
R21ES027391

Mitochondrial Targeted Biofuels as Countermeasures Against Chemical Threats 
Todd J. Kilbaugh, M.D.    
Children's Hospital of Philadelphia
R21NS103826

The Carboxylesterase Knockout Mouse as a Model to Evaluate the Efficacy of Delayed Medical Countermeasures Against Soman Exposure 
Lucy Lange, Ph.D.    
Geneva Foundation
R21NS103820

Countermeasure Therapeutics for Acute Lung Injury 
George D. Leikauf, Ph.D.    
University of Pittsburgh, Pittsburgh
R21ES027390

Formulation and Encapsulation of Enzyme Countermeasures Against Organophosphorus Compounds
Thomas J. Magliery, Ph.D.
Ohio State University
R21NS084899

Amelioration of Soman-induced Neuropathology with NAAG-related Compounds
Joseph T. McCabe, Ph.D.
Henry M Jackson Foundation for the Advancement of Military Medicine
R21NS089488

Computationally Designed Stable Artificial Phosphotriesterases for Detoxification of Organophosphorus Agents
Jin K. Montclare, Ph.D.
New York University
R21NS103831

An Approach Toward Antidotes for Phosphine
Linda Pearce, Ph.D.
University of Pittsburgh, Pittsburgh
R21ES029310

New Chelating (decorporating) Agents for Azide
Linda Pearce, Ph.D.
University of Pittsburgh, Pittsburgh
R21NS098989

Overlay Independent X-ray Data Analysis for Enhanced Oxime OP-ChE Reactivation
Zoran Radic, Ph.D.
University of California, San Diego
R21NS098998

Epigenetic Attenuation of Long-term Effects of Nerve Agents
Doodipala S. Reddy, Ph.D.
Texas A&M University Health Science Center
R21NS099009

Developing and Evaluating Countermeasures Against Tetramethylenedisulfotetramine
Michael Shakarjian, Ph.D.
New York Medical College
R21NS084900

Phosgene Oxime Cutaneous Toxicity and Mechanisms to Identify Therapeutic Targets
Neera Tewari-Singh, Ph.D.
University of Colorado, Denver
R21AR073544

Toxin-specific and Symptomatic Drugs in Combination with Novel Neuroprotectants Effectively Counteract DFP-induced Long-term Neurotoxicity
Thimmasettappa Thippeswamy, Ph.D.
Iowa State University
R21NS099007

Glutathione Monoesters to Counteract Ocular Chemical Injury
Vasilis Vasiliou, Ph.D.
Yale University
R21EY026776

Atropine for Chlorine Inhalation Toxicity
Livia A. Veress, M.D.
University of Colorado, Denver
R21ES026830
 


Contracts, Inter-Agency Agreements, and Other Resources

CounterACT Preclinical Development Facility (CPDF) 
Carol Green, Ph.D., D.A.B.T.   
SRI International
N01NS62369


Interagency Agreements (IAAs) between the National Institutes of Health and the Department of Defense
Chemicals Affecting Skin, Eyes & Mucous Membranes - Toxic Vesicants and Industrial Chemicals
Chemicals Affecting the Nervous System - Anticonvulsants and Neuroprotectants
Cyanide Diagnostics and Efficacy Testing of Next Generation Cyanide Antidotes
Chemicals Affecting the Respiratory Tract - Pulmonary Toxicants
James F. Dillman, Ph.D.
  
U.S. Army Medical Research Institute of Chemical Defense